- AnaptysBio ( NASDAQ: ANAB ) will receive a $5M milestone payment from GlaxoSmithKline ( NYSE: GSK ) this quarter when the UK pharma giant doses the first patient in a phase 3 trial of Jemperli (dostarlimab) + cobolimab.
- Earlier Wednesday morning, GSK ( GSK ) said it was advancing both arms of the COSTAR trial into phase 3 -- Jemperli + chemotherapy, and cobolimab + Jemperli + chemotherapy in advanced non-small cell lung cancer.
- AnaptysBio ( ANAB ) licensed Jemperli and cobolimab to GSK ( GSK ). Cobolimab is known as a anti-TIM-3 antagonist.
- Under terms of the collaboration, AnaptysBio ( ANAB ) receives an 8%-25% royalty on Jemperli sales: 8% when global net sales are below $1B, while sales above $1B are a 12%-25% royalty. Royalties for potential sales of cobolimab are from 4%-8%.
- Seeking Alpha's Quant Rating views AnaptysBio ( ANAB ) as a buy with high marks for momentum and revisions .
For further details see:
AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial